Navigation Links
ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
Date:5/5/2008

Conference call scheduled for May 12, 2008 at 1:30 p.m. (Pacific);

simultaneous webcast at http://www.adventrx.com

SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced that it will host a conference call with simultaneous webcast to discuss first quarter 2008 results on Monday, May 12th, 2008 at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Evan M. Levine, Chief Executive Officer and President, and Mark N. K. Bagnall, Chief Financial Officer and Executive Vice President, will host the conference call.

The conference call may be accessed by dialing (888) 215-7013 for domestic callers and (913) 312-1235 for international callers. The webcast will be available live via the Internet by accessing ADVENTRX's web site at http://www.adventrx.com under "Investors". Replays of the webcast will be available for 30 days on ADVENTRX's web site, and a phone replay will be available through May 17, 2008 by dialing (888) 203-1112 and entering the passcode 5439297.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in- licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference
2. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference
3. ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference
4. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman ... Van Allen have signed a joint enrollment and degree completion agreement. The ... associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students to ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , ... Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated ... hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We ...
(Date:2/5/2016)... ... 05, 2016 , ... Regular gym users know the routine: each January, they ... access the treadmills. It’s a predictable trend. After the excesses of November and December, ... shape by joining gyms, starting new walking or running routines, or signing up for ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... in the 2015 Best in KLAS: Software & Services for HIT Implementation Support ... in KLAS report independently ranks vendor performance by healthcare executives, managers and clinicians ...
(Date:2/5/2016)... WORCESTER, MA (PRWEB) , ... February 05, 2016 , ... ... latest in tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal ... cutting-edge option with unmatched results. , Developed by Cynosure, the PicoSure has been approved ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Edwards Lifesciences ... patient-focused innovations for structural heart disease and critical care ... accelerated share repurchase (ASR) agreement with Morgan Stanley & ... stock.  This repurchase is part of the Company,s previously ... the Company,s common stock.  --> ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:2/4/2016)... 2016  Omnicell, Inc. (NASDAQ: OMCL ), a leading ... systems, today announced results for its fiscal year and ... --> GAAP results: Revenue for the ... million or 4.1% from the third quarter of 2015, ... quarter of 2014. Revenue for the year ended December 31, ...
Breaking Medicine Technology: